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a b s t r a c t
Objective. We sought to determine whether racial disparities in tumor characteristics among uterine
cancer patients persisted, and varied by age, in an equal-access healthcare population.
Methods. The distributions of tumor histology, stage and grade by race were compared for uterine cancers
diagnosed from 1990 to 2003 using data from the U.S. Department of Defense's Automated Central Tumor
Registry. Comparisons were conducted overall and stratiﬁed by age (b 50, ≥ 50) using the Chi-square test.
Results. Of 2582 uterine tumors identiﬁed, 2057 (79.7%) were diagnosed among White women and 183
(7.1%) among Black women. Among all women analyzed, Blacks were more likely than Whites to present with
non-endometrioid tumors (47.7% vs 23.5%, p b 0.01), non-localized tumors (31.8% vs 24.5%, p = 0.02), and poorly
differentiated tumors (20.5% vs 15.0%, p b 0.01). Among women 50 years and older, similar signiﬁcant racial
disparities were observed. However, no signiﬁcant racial differences were observed among young patients. When
comparisons were restricted to endometrioid histology adenocarcinomas, trends in age-speciﬁc disparities for
older women were observed.
Conclusions. Our study suggests that racial disparities in uterine cancers persist between Blacks and Whites
in an equal-access population. Blacks endure higher stage and grade tumors, and more aggressive histologies. This
disparity in clinicopathologic factors is conﬁned to women older than 50 years. Multiple factors such as racial
variation in age-related health knowledge/behavior and estrogen metabolism may be related to the racial disparity.
Published by Elsevier Inc.

Introduction
Uterine corpus cancer is the most common gynecologic malignancy
in the United States, accounting for approximately 6% of all tumors
diagnosed [1]. The vast majority of these tumors arise from the
endometrium. The American Cancer Society estimated that 43,470
new cases of and 7950 deaths from endometrial cancer would occur
during 2010 [1]. While uterine cancer incidence rates are lower among
Black women than White women, [2] Blacks are more often diagnosed
with aggressive histologic subtypes, advanced tumor stages, and/or
higher tumor grades, and they suffer a correspondingly worse prognosis
[2–21]. Indeed, the disease-speciﬁc mortality rate for Black women is
nearly double that endured by White women [2].

☆ The views expressed in this article are those of the authors and do not necessarily
reﬂect the ofﬁcial policy or opinion of the Department of Defense or the United States
Army or Navy, nor the US Government.
⁎ Corresponding author.
E-mail address: john.farley@us.army.mil (J.H. Farley).

The etiology of the observed survival disparities between Black and
White women likely is multi-factorial [5–7,10,12,13,15–17,20–27].
One of the often-cited explanations is racial variation in access to care
[5–7,12,13,22,23]. With decreased access, Black women may see
physicians less often or delay in seeking care, and thereby they may
present at later stages or with more aggressive histologies [6,7,10,12,13,
22,23,28,29]. Treatment differences, including inconsistencies in primary and adjuvant therapies, have also been implicated in the
disparities in outcome and survival [7,9,12,13,15,17,22,23,26]. Multiple
studies have evaluated contributions of various socioeconomic factors
to endometrial cancer disparities, yet often they have been hampered by
an inability to adequately control for confounding variables. Elucidation
and clariﬁcation of any clinicopathologic disparities between Blacks
and Whites could provide improved individualized treatments for
endometrial cancer patients. The Department of Defense's (DoD)
Military Health System provides a unique setting to investigate racial
disparities because equal healthcare access is provided regardless of age,
race, gender, or socioeconomic status [30].
Kost, et al. [30] previously evaluated clinicopathologic factors of
endometrial cancer by race among DoD beneﬁciaries and found that
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White women presented with more favorable tumor stage, grade,
and histologic types. The objective of the current study was to assess
whether these previously described disparities between White and
Black DoD beneﬁciaries persisted using the DoD-wide cancer registry
data and whether the racial differences varied by age.

Materials and methods
After obtaining Institutional Review Board approval, uterine cancer
data among DoD beneﬁciaries were extracted from the Automated
Central Tumor Registry (ACTUR). Originating in 1986, ACTUR collects and
tracks cancer data for DoD beneﬁciaries diagnosed or treated at military
treatment facilities, including active-duty military personnel, retirees,
and their dependents. Local tumor registrars, in direct consultation
with corresponding gynecologic oncologists, abstract and enter data from
a newly-diagnosed cancer patient's pertinent clinical history. Details
regarding the tumor (e.g., site, histology and stage) and the patient (e.g.,
gender, race and age at diagnosis) then are forwarded for inclusion in the
ACTUR database.
Clinical and pathologic data were extracted for all patients with
invasive endometrial cancer included in the ACTUR database between
1990 and 2003. While all submitted data undergo veriﬁcation, data
prior to 1990 were excluded to minimize potential incomplete
recording during the initial years of the cancer registry. Previously
described methods [31] developed using national and state cancer
registry guidelines [32,33] were employed to identify and consolidate
duplicate records. Abstracted variables included race, age at diagnosis,
histology, grade, and stage. Patients were classiﬁed into groups: by
age (b50 years or ≥50 years), and by race. Age was used as a proxy for
menopausal/hormonal status. Various age thresholds for menopause
have previously been employed in the literature. We selected a
threshold of age 50 years in accordance with an investigation which
revealed that, above this threshold, age-speciﬁc survival in endometrial cancer decreased signiﬁcantly [34]. Race was determined by the
primary gynecologic oncologist at the time of diagnosis or treatment
using observation or beneﬁciary health record data, and was recorded
in the respective local tumor registry.
Cases were categorized using the appropriate edition of the
International Classiﬁcation of Diseases for Oncology (ICD-O) [35–37].
The previous versions of ICD-O codes were converted to the third
edition (ICD-O-3) by applying established guidelines. Uterine corpus
cancers were deﬁned using the primary site (topography) codes C540–
C543, C548–C549 and C559. Histology was deﬁned using the ICD-O-3
morphology codes and classiﬁed as endometrioid [8380 (endometrioid
adenocarcinoma), 8382 (endometrioid adenocarcinoma secretory
variant), 8383 (endometrioid adenocarcinoma ciliary cell variant),
8140 (adenocarcinoma NOS)], non-endometrioid (all other known
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morphology), and unknown (9999). Central pathologic review of
pathologic specimens was not performed.
Tumors were graded by extent of differentiation: well, moderately,
poorly, undifferentiated, or unknown. One ambiguous case was
excluded secondary to having a tumor grade designated as “B-cell,”
which suggested a non-uterine primary. Stage was categorized as local,
regional, distant or unknown by combining Surveillance, Epidemiology
and End Results (SEER) Summary Stage variables. Racial differences in
the tumor characteristics were assessed using the Chi-square or Fisher's
exact test for small sample sizes. The signiﬁcance level was speciﬁed as
p b 0.05. All calculations were performed using SAS Statistical Software,
version 9.1 (SAS Institute, Inc., Cary, NC).

Results
Query of the ACTUR database revealed a total of 2582 eligible
uterine tumors. There were 1924 (74.5%) tumors of endometrioid
histology and 655 (25.4%) tumors of non-endometrioid histologic
subtype, even though a central pathologic review and conﬁrmation of
histologic characteristics were not performed [Table 1]. Only 3 cases
were designated as having unknown histology [Table 1]. Abstracted
race designations included White, Black, Other, and Unknown. We
restricted our analysis to the two racial categories which were
speciﬁed discretely (White and Black). Of the 2582 tumors abstracted,
2057 (79.7%) were diagnosed among White women and 183 (7.1%)
were diagnosed among Blacks [Table 1]. Forty-six tumors occurred in
women on active duty, while the remaining tumors were diagnosed in
retirees, dependents and family members [Table 1]. Given the small
numbers of tumors in active duty women, we restricted our analysis
to comparisons involving the non-active duty beneﬁciary population.
Of the 2536 tumors in non-active duty beneﬁciaries, 2022 (79.7%)
were identiﬁed in White women and 176 (6.9%) were identiﬁed in
Blacks [Table 1].
Mean age at diagnosis in each of the age categories was similar for
both Blacks and Whites. For young women (b50 years), the mean age
at diagnosis was 42.1 years for Whites and 40.8 years for Blacks
(p = 0.23), while for older women (≥50 years), the mean ages at
diagnosis were 63.6 years and 63.0 years for Whites and Blacks,
respectively (p = 0.43) [Table 2]. Similar results were noted when
restricting the analysis to endometrioid histology [Table 2]. Not
surprisingly, statistically signiﬁcant distributions toward lower stage
and grade favoring endometrioid histology were observed irrespective of age stratiﬁcation (data not shown).
More Black women than White women were predisposed to nonendometrioid histology, (47.7% vs 23.5%, p b 0.01) [Table 3]. This
relationship persisted when evaluating the older age group, with
more Blacks than Whites older than 50 years presenting with non-

Table 1
Racial comparison of uterine cancer by tumor histology and duty status at diagnosis among all Department of Defense healthcare beneﬁciaries, Automated Central Tumor Registry
1990–2003.
Duty status

Active duty

Non-active duty

All beneﬁciaries

a

Histology

Endometrioid
Non-endometrioid
Unknown
Total
Endometrioid
Non-endometrioid
Unknown
Total
Endometrioid
Non-endometrioid
Unknown
Total

White

Black

Other

Unknown

Total

N

%

N

%

N

%

N

%

N

%

26
9
0
35
1545
475
2a
2022
1571
484
2a
2057

74.3
25.7
0.0

6
1
0
7
92
84
0
176
98
85
0
183

85.7
14.3
0.0

2
0
0
2
197
69
0
266
199
69
0
268

100.0
0.0
0.0

0
2
0
2
56
15
1
72
56
17
1
74

0.0
100.0
0.0

34
12
0
46
1890
643
3a
2536
1924
655
3a
2582

73.9
26.1
0.0

76.4
23.5
0.1
76.4
23.5
0.1

One case was excluded secondary to B-cell histology suggesting a non-uterine primary.

52.3
47.7
0.0
53.6
46.4
0.0

74.1
25.9
0.0
74.3
25.7
0.0

77.8
20.8
1.4
75.7
23.0
1.4

74.5
25.4
0.1
74.5
25.4
0.1
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Table 2
Observed age comparisons by age group and by race among non-active duty
Department of Defense healthcare beneﬁciaries, Automated Central Tumor Registry,
1990–2003.
White

Black
a

Histology

Age

N

Mean

Std

All

b50
≥50
b50
≥50

370
1652
270
1275

42.1
63.6
42.9
63.3

0.32
0.20
0.34
0.23

Endometrioid
a
b

N

Mean

Stda

p-valueb

36
140
22
70

40.8
63.0
40.8
63.4

1.20
0.67
1.43
0.84

0.23
0.43
0.10
0.94

Std Dev = standard deviation.
Reported p-value from t-test.

Discussion

endometrioid histology (50% vs 22.7%, respectively, pb 0.01) [Table 3]. No
such pattern was observed in young women [Table 3].
With respect to stage at diagnosis, more Whites than Blacks
presented with localized disease (75.6% vs 68.2%, p = 0.02) [Table 3].
For women at least 50 years old, more White women were diagnosed
with localized disease compared with Black women (75.1% vs 65.7%,
p b 0.01), while no racial differences in stage at diagnosis were noted in
young women [Table 3]. Similar results were observed when considering grade at diagnosis. White women, in general, more often
presented with well-differentiated tumors (45.2% vs 34.7%, p b 0.01)
Table 3
Racial comparison of uterine cancer by age, tumor histology, stage and grade at diagnosis
among non-active duty Department of Defense healthcare beneﬁciaries, Automated
Central Tumor Registry 1990–2003.
Age at
Tumor characteristic
diagnosis

White

All

1545
475
2
1,528
256
113
125
913
518

b 50

≥ 50

a

Histology Endometrioid
Non-endometrioid
Unknown
Stage
Local
Regional
Distant
Unknown
Grade
Well differentiated
Moderately
differentiated
Poorly
differentiated
Undifferentiated
Unknown
Histology Endometrioid
Non-endometrioid
Unknown
Stage
Local
Regional
Distant
Unknown
Grade
Well differentiated
Moderately
differentiated
Poorly
differentiated
Undifferentiated
Unknown
Histology Endometrioid
Non-endometrioid
Unknown
Stage
Local
Regional
Distant
Unknown
Grade
Well differentiated
Moderately
differentiated
Poorly
differentiated
Undifferentiated
Unknown

[Table 3]. No signiﬁcant racial variations between young White and
Black women were observed, yet Whites were more likely to be
diagnosed with well-differentiated tumors than Blacks (43.8% vs 29.3%,
p b 0.01) when women older than 50 years were evaluated [Table 3].
When comparisons were restricted to endometrioid histology, although
there was a tendency for White women to have more favorable tumors,
none of the racial differences were signiﬁcant [Table 4]. However,
among older women, the racial difference in tumor grade was
borderline signiﬁcant with more Blacks than Whites diagnosed with
poorly differentiated tumors (20.0% vs 12.9%, p = 0.06) [Table 4].

p valuea

Black

76.4%
92 52.3% b0.01
23.5%
84 47.7%
0.1%
0
0.0%
75.6% 120 68.2%
0.02
12.7%
24 13.6%
5.6%
20 11.4%
6.2%
12
6.8%
45.2%
61 34.7% b0.01
25.6%
31 17.6%

304 15.0%

36 20.5%

17
270
270
100
0
288
44
17
21
189
84

2
46
22
14
0
28
5
1
2
20
3

0.8%
13.4%
73.0%
27.0%
0.0%
77.8%
11.9%
4.6%
5.7%
51.1%
22.7%

42 11.4%
3
52
1275
375
2
1,240
212
96
104
724
434

0.8%
14.1%
77.2%
22.7%
0.1%
75.1%
12.8%
5.8%
6.3%
43.8%
26.3%

1.1%
26.1%
61.1%
38.9%
0.0%
77.8%
13.9%
2.8%
5.6%
55.6%
8.3%

This study conﬁrms that the often-cited racial disparity in clinicopathologic characteristics between Blacks and Whites [2–21] remains evident
despite equal access to care. Moreover, we demonstrate that this racial
variation is conﬁned to older women, with Blacks prejudicially enduring
non-endometrioid, non-localized, and poorly differentiated tumors.
The data may suggest similar trends when considering endometrioid
histologies alone.
Other investigators have attempted to evaluate the effect of
socioeconomics on racial disparities. Hill, et al. [10] reported an
analysis of data from the Black/White Cancer Survival Study (BWCSS).
This study found that poverty index inﬂuenced grade at diagnosis. Yet,
it necessarily was hampered by the drawbacks associated with any
population-based evaluation, [38] as well as by selection biases arising
both from exclusion of cases with incomplete interview records and
from failure to capture grossly underserved patients. Barrett, et al. [6]
also evaluated a cohort from the BWCSS; those results likewise were
affected by the disadvantages hindering Hill, et al. [10]. Kost, et al. [30]
evaluated an analogous DoD beneﬁciary population; however, our
investigation expanded on both the population and goals considered
in that study.
Table 4
Racial comparison of endometrioid histology by age, stage and grade at diagnosis
among non-active duty Department of Defense healthcare beneﬁciaries, Automated
Central Tumor Registry 1990–2003.
White

All

1,211
181
57
96
792
435

78.4%
11.7%
3.7%
6.2%
51.3%
28.2%

67
10
7
8
45
19

72.8% 0.20
10.9%
7.6%
8.7%
48.9% 0.17
20.7%

192
4
122
224
27
6
13
155
68

12.4%
0.3%
7.9%
83.0%
10.0%
2.2%
4.8%
57.4%
25.2%

17
0
11
16
3
1
2
17
2

18.5%
0.0%
12.0%
72.7% 0.34
13.6%
4.5%
9.1%
77.3% 0.22
9.1%

28
1
18
987
154
51
83
637
367

10.4%
3 13.6%
0.4%
0
0.0%
6.7%
0
0.0%
77.4% 51 72.9% 0.23
12.1%
7 10.0%
4.0%
6
8.6%
6.5%
6
8.6%
50.0% 28 40.0% 0.06
28.8% 17 24.3%

0.13

0.95

0.14
b 50

6 16.7%
1
6
70
70
0
92
19
19
10
41
28

2.8%
16.7%
50.0% b0.01
50.0%
0.0%
65.7% b0.01
13.6%
13.6%
7.1%
29.3% b0.01
20.0%

262 15.9%

30 21.4%

14
0.8%
218 13.2%

1
0.7%
40 28.6%

Chi-square or Fisher's exact p-value in comparison to Whites.

≥ 50

a

Stage

Local
Regional
Distant
Unknown
Grade Well differentiated
Moderately
differentiated
Poorly differentiated
Undifferentiated
Unknown
Stage Local
Regional
Distant
Unknown
Grade Well differentiated
Moderately
differentiated
Poorly differentiated
Undifferentiated
Unknown
Stage Local
Regional
Distant
Unknown
Grade Well differentiated
Moderately
differentiated
Poorly differentiated
Undifferentiated
Unknown

Black

p-valuea

Age at
Tumor characteristic
diagnosis

164 12.9% 14 20.0%
3
0.2%
0
0.0%
104
8.2% 11 15.7%

Chi-square or Fisher's exact p-value in comparison to Whites.
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Liu, et al. [12] addressed delay in presentation to care, ﬁnding no
signiﬁcant difference in time to presentation following the onset of
vaginal bleeding between Blacks and Whites, yet simultaneously
demonstrating persistent racial disparities in histology, stage and
grade burdening Black women. While these results are provocative,
the study included several drawbacks. In addition to involving only a
small number (thirty-nine) of Black patients, the results were
inﬂuenced by an undisclosed number of excluded patients who
underwent radiation therapy alone due to severe medical conditions.
This potentially introduced bias as Black patients have been shown to
be disproportionately affected by poor overall health status [39].
Furthermore, while the investigation evaluated all patients meeting
inclusion criteria at their institution, it made no comment regarding
the uniformity of access to care for the hospital's catchment area.
The prognostic signiﬁcance of age in endometrial cancer has been
established previously, although the critical age is debatable [3,5,9,11,
16,20,34,40]. Our stratiﬁcation used 50 years old as a surrogate for
menopausal status, based upon prior demonstration of a signiﬁcant
decrease in endometrial cancer survival after that threshold [34]. Thus,
our results suggest that racial disparities in endometrial cancers are
conﬁned to postmenopausal Blacks when compared to Whites, and no
such relationship exists for premenopausal women. Furthermore, when
we excluded non-endometrioid histologies, a similar trend emerged,
implying that the observed disparities may not be exclusively due to the
preponderance of high-risk tumors in Blacks. This association with
menopausal status may suggest variable estrogen exposure between
racial groups, a mechanism that is particularly relevant in the absence of
an intact hypothalamic–pituitary–ovarian axis.
The endometrium is hormonally sensitive, so it is not surprising
that alterations in the hormonal milieu may contribute to carcinogenesis. The majority of endometrial cancers are diagnosed in the
setting of estrogen excess in patients with risk factors for either
unopposed endogenous or exogenous estrogen exposure. Tumors arising
in this milieu are predominantly type I, or of endometrioid subtype
[40,41]. Type II tumors, in contrast, are less common, demonstrate worse
differentiation, and portend a less favorable prognosis [40,41]. Typically of
uterine papillary serous or clear cell histologic subtype, type II tumors are
thought to develop independent of estrogen exposure, arising instead in
the setting of an atrophic endometrium [40,41]. Dedifferentiation from
type I to type II may also occur [29].
Differential estrogen metabolism has long been implicated in
development of hormonally-sensitive cancers [5,6,10,16,41–43]. Within
the endometrium, estrogen induces transcriptional changes that cause
downstream promotion of cell proliferation and inhibition of apoptosis
[43–45]. In addition, depurinating adducts from estrogen's oxidative
metabolites are believed to be carcinogenic [43]. Alterations in estrogen
metabolism also have been implicated in oncogenesis through gene
polymorphisms [42,45,46]. The cytochrome p450 enzyme CYP1B1, for
example, has been linked to breast cancer development [45,47]. CYP1B1
upregulation is thought to instigate cellular damage by catalyzing the
hydroxylation of estrogens, and it can disrupt cellular proliferation
through interference with cell cycle regulation [29,45]. Polymorphisms
of the CYP1B1 codons result in hyperactivation, and have been shown to
impart increased incidence in endometrial cancer, [45,46] though the
ﬁndings have been conﬂicting [42,46]. In a separate pathway, estrogens
bind to the estrogen receptor ligand binding domain, resulting in
stimulation of cell proliferation in these target tissues [46]. Polymorphisms of estrogen receptor alpha likewise have been implicated in
conferring increased risk of endometrial cancers in a recent pilot study
by Sliwinski, et al [46]. Concurrent investigation into the seventransmembrane estrogen receptor GPR30, whose activation is known
to promote endometrial proliferation, has highlighted a potential novel
pathway for estrogen-mediated endometrial carcinogenesis [44].
Estrogen metabolism is an obvious focus for investigation into the
etiology of the observed racial disparities in endometrial cancer. Indeed,
racial variations in exogenous hormone use previously have been
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identiﬁed as contributors to differences in outcome between Blacks and
Whites [10,16,42]. While unopposed exogenous estrogen serves as a
risk factor for endometrial cancer development, the resulting tumors are
typically of the more favorable type I biology and therefore are
associated with better prognosis [10,40–42]. Estrogen replacement
more often is prescribed to Whites than Blacks, in part perhaps,
contributing to higher rates of type I tumors among Whites [6,42].
However, when controlling for exogenous hormone use, the observed
disparities in rates of type I tumors remain, suggesting that other aspects
of tumor biology also must be implicated [16]. Endogenous estrogen
exposure has also been cited. Direct associations between the metabolic
syndrome and its individual components and endometrial cancer risk
have been previously described [48]. Brancati, et al. [39] reported that
Blacks suffer a two-fold increased risk of diabetes when compared with
Whites, even when controlling for the usual surrogates for obesity, BMI
and waist-to-hip ratio. Related factors may account for the excess
endometrial cancer risk we demonstrated in postmenopausal Black
women.
The role of estrogen in racial disparities was highlighted in a
retrospective analysis of Gynecologic Oncology Group (GOG) 137 data
comparing recurrence-free and overall survival between Whites and
Blacks receiving post-operative estrogen replacement therapy for
surgically treated, early-stage endometrial cancer [16] .While the Blacks
on the treatment arm endured a relative risk of recurrence of 11.2 when
compared with Whites, a similar relationship was not observed for the
Blacks on the placebo arm [16]. The study concluded that Blacks may be
at increased risk of recurrence when maintaining post-operative
estrogen therapy and suggested that potential differences in estrogen
metabolism could be a source of the racial variation [16].
Molecular alterations may contribute to differences in outcome
between Blacks and Whites with endometrial cancer. An analysis of 147
patients diagnosed with endometrial cancer between 1995 and 2001
sought to analyze and compare the molecular proﬁles in endometrial
cancer in White and Black patients using a number of known molecular
markers [18]. Black patients had more type II carcinoma than White
patients with high p53 protein expression increased signiﬁcantly among
the Black patients (49% vs. 30%, P = 0.035) versus White patients [18].
Studies have shown that p53 over-expression in endometrial cancer is
associated with a more aggressive tumor characteristics and behavior
including poor differentiation, deep myometrial invasion and lymph
node metastases [15–18].
In another study 140 stage III/IV endometrial adenocarcinomas were
screened for mutations in the PTEN gene [14]. Black women had cancers
with signiﬁcantly higher stage and grade that were more often
nonendometrioid. PTEN mutation was seen in 14% cancers and was
associated with endometrioid histology and more favorable survival.
The frequency of PTEN mutations was signiﬁcantly higher in Whites
(22% vs 5%, P = 0.006) [14]. This suggests that differences in the
frequency of PTEN mutations contribute to the racial disparity in
endometrial cancer survival.
One limitation of our study is the lack of uniformity in race reporting
within the ACTUR database. While the primary gynecologic oncologist
establishes the race designation forwarded to the registry, this provider typically ascertains the patient's race using the DoD's electronic
beneﬁciary health record database. Race determination in this system
is made upon enrollment as a military beneﬁciary, and arises from a
combination of self- and administrative reporting. The balance of racial
categories in ACTUR is determined through physician-reporting. As these
race designations are unconﬁrmed, they may lead to misclassiﬁcation that
could attenuate the differences we reported between Blacks and Whites.
Such attenuation could mask true differences in younger women or
underestimate the differences observed in older women. Furthermore,
the heterogeneous distribution of military treatment facilities may
introduce selection bias in the patients reported to ACTUR, as remote
patients are often referred for care in the civilian sector and therefore are
not captured. This bias affects retired personnel and their dependents
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more signiﬁcantly than active duty members. Given the small numbers of
White [35] and Black [7] active duty patients, we focused on non-active
duty beneﬁciaries and potentially introduced another source of bias.
Finally central pathologic review of all tissue and surgical specimens
was not performed in this retrospective database review. This may bias
those patients treated at academic centers, historically White patients,
where specialized pathologists were available. Specialized pathologic
review should allow more accurate diagnosis of advanced grade and
poor prognosis histologic specimens. All patients included in this study
were initially treated at medical centers with specialized pathologic
review. Also, even among experts, reproducibility of endometrial cancer
pathologic diagnosis can be suspect [10,49]. Evaluations of low grade
and atypical hyperplastic lesions of the endometrium are notoriously
poor [10,49]. Additionally, although FIGO grading has signiﬁcant
predictive value, the reproducibility of Grade 2 is limited such that a
binary grading system has been proposed. Even with the binary system
reproducibility among pathologists is poor and varies from only 80% to
85% [49].
Our study conﬁrms that racial disparities in uterine cancers persist
between Blacks and Whites in an equal access to care environment,
suggesting that a signiﬁcant proportion of the observed disparities
cannot be attributed solely to unequal access to care. Furthermore, we
found that older Black women carried the burden of the disparate
tumor characteristics. Similar trends observed when considering
endometrioid histology alone suggest that the disparities cannot be
entirely attributed to racial differences histology. Further investigation into the nature of endometrial cancer disparity is warranted,
particularly in order to conﬁrm these results in other populations for
which confounding factors (such as socioeconomics and access to
care) are adequately controlled.
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